Longitudinal Performance of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Results from the Prospective, Observational, 5-Year PURE Registry - Scorecard - MDSpire
Advertisement
Long-Term Evaluation of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Findings from the 5-Year Prospective PURE Registry Study
Clinical Scorecard: Long-Term Evaluation of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Findings from the 5-Year Prospective PURE Registry Study
At a Glance
Category
Detail
Condition
Psoriasis and Psoriatic Arthritis (PsA)
Key Mechanisms
Identification of patients at increased risk for PsA using the PEST questionnaire.
Target Population
Adult patients (≥ 18 years) with moderate to severe chronic plaque-type psoriasis.
Care Setting
Longitudinal observational study in clinical practice.
Key Highlights
PEST is a self-administered questionnaire with five questions related to PsA risk.
Many initially PEST negative patients became PEST positive over 5 years.
PEST has demonstrated good sensitivity and specificity for identifying PsA.
The study reinforces the use of PEST as a standardized tool in clinical practice.
The PURE registry enrolled 2500 patients across Canada and Latin America.
Guideline-Based Recommendations
Diagnosis
Use PEST annually or semi-annually to identify PsA.
Management
Timely referral to rheumatologists for expert diagnosis and optimal outcomes.
Monitoring & Follow-up
Follow patients with PEST scores over time to assess disease progression.
Risks
Irreversible joint damage can occur if PsA is not diagnosed early.
Patient & Prescribing Data
Patients initiating treatment for moderate to severe psoriasis.
Patients treated with secukinumab or other approved therapies.
Clinical Best Practices
Conduct regular assessments using the PEST questionnaire.
Ensure dermatologists are knowledgeable in assessing joint and skin symptoms.
by Jennifer Beecker, Lorne Albrecht, Ignacio Dei-Cas, Melinda Gooderham, Charles Lynde, Kim A. Papp, Paul Keown, Antonio Vieira, Mahmoud S. Farag, Marie Maguin, Tanya Zappitelli, Philip S. Helliwell
